Spectral AI Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY Revenue (est.)
$18.5Mnext fiscal year
FY EPS (est.)
-$0.51next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Conference Call | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
BARDA Contract Funding Progress Quarterly31.7M
Annual Revenue Guidance Annually18.5M
Cash Balance Quarterly11.7MTarget: Maintain sufficient runway for commercialization
Watch Items
- Commercial Deployment of DeepView System for Burn IndicationTrigger: First commercial sales by year-end 2026Action: Monitor sales pipeline, hospital procurement cycles, and initial commercial revenue generation.
- Handheld DeepView Device Prototype DevelopmentTrigger: Prototype completion by end of Q2 2026Action: Track progress under the DoD/MTEC Phase II contract extension to ensure prototype delivery.
- International Regulatory Approvals (CE Mark & UKCA Updates)Trigger: Expanded UKCA authorization and CE Mark progress in late 2026Action: Monitor regulatory submissions and clinical trial readouts in the UK and Europe.
Research as of 19 Jun 2026